Evan T. Ogburn

888 total citations
11 papers, 567 citations indexed

About

Evan T. Ogburn is a scholar working on Pharmacology, Infectious Diseases and Oncology. According to data from OpenAlex, Evan T. Ogburn has authored 11 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 6 papers in Infectious Diseases and 4 papers in Oncology. Recurrent topics in Evan T. Ogburn's work include Pharmacogenetics and Drug Metabolism (8 papers), HIV/AIDS drug development and treatment (6 papers) and Drug Transport and Resistance Mechanisms (3 papers). Evan T. Ogburn is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), HIV/AIDS drug development and treatment (6 papers) and Drug Transport and Resistance Mechanisms (3 papers). Evan T. Ogburn collaborates with scholars based in United States, Germany and Japan. Evan T. Ogburn's co-authors include Zeruesenay Desta, Yingying Guo, Cong Xu, David Jones, David A. Flockhart, Cong Xu, Anuradha Ramamoorthy, Swarajya Lakshmi Vattem Venkata, Mitesh Sanghvi and Michael E. Goldberg and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

Evan T. Ogburn

11 papers receiving 563 citations

Peers

Countries citing papers authored by Evan T. Ogburn

Since Specialization

Citations

This map shows the geographic impact of Evan T. Ogburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan T. Ogburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan T. Ogburn more than expected).

Fields of papers citing papers by Evan T. Ogburn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan T. Ogburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan T. Ogburn. The network helps show where Evan T. Ogburn may publish in the future.

Co-authorship network of co-authors of Evan T. Ogburn

This figure shows the co-authorship network connecting the top 25 collaborators of Evan T. Ogburn. A scholar is included among the top collaborators of Evan T. Ogburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan T. Ogburn. Evan T. Ogburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Citalopram and escitalopram plasma drug and metabolite concentrations: genome‐wide associations 2014 ·British Journal of Clinical Pharmacology ·Yuan Ji, Daniel J. Schaid, Zeruesenay Desta, Michiaki Kubo, Anthony Batzler, Karen Snyder, Taisei Mushiroda, Naoyuki Kamatani, Evan T. Ogburn, Daniel K. Hall‐Flavin, David A. Flockhart, Yusuke Nakamura, David A. Mrazek, Richard M. Weinshilboum	61
2	CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer 2013 ·SpringerPlus ·Richard R. Love, (unknown), David A. Flockhart, Todd C. Skaar, Evan T. Ogburn, Anuradha Ramamoorthy, Gemma B. Uy, Adriano V. Laudico, Nguyễn Văn Định, (unknown), Ta Van To, Gregory Young, Erinn M. Hade, David Jarjoura	25
3	Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent 2013 ·The Pharmacogenomics Journal ·Véronique Michaud, (unknown), (unknown), Evan T. Ogburn, (unknown), (unknown), Zereunesay Desta	16
4	Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo 2012 ·Clinical Pharmacology & Therapeutics ·Henriette E. Meyer zu Schwabedissen, Stefan Oswald, (unknown), Ali Nassif, Christiane Modeß, Zeruesenay Desta, Evan T. Ogburn, Milka Marinova, Dieter Lütjohann, Christin Spielhagen, (unknown), H K Kroemer, Werner Siegmund	31
5	Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers 2012 ·Clinical Pharmacology & Therapeutics ·Véronique Michaud, Evan T. Ogburn, (unknown), (unknown), Troy C. Quigg, David A. Flockhart, Zeruesenay Desta	35
6	Stereoselective and regiospecific hydroxylation of ketamine and norketamine 2012 ·Xenobiotica ·Zeruesenay Desta, Ruin Moaddel, Evan T. Ogburn, Cong Xu, Anuradha Ramamoorthy, Swarajya Lakshmi Vattem Venkata, Mitesh Sanghvi, Michael E. Goldberg, Marc C. Torjman, Irving W. Wainer	91
7	Effects of the CYP2B66 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo 2012 ·Drug Metabolism and Disposition* ·Cong Xu, Evan T. Ogburn, Yingying Guo, Zeruesenay Desta	55
8	Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers 2012 ·Clinical Pharmacology & Therapeutics ·Stefan Oswald, Henriette E. Meyer zu Schwabedissen, Ali Nassif, Christiane Modeß, Zeruesenay Desta, Evan T. Ogburn, Jörg Mostertz, Markus Keiser, Jingying Jia, (unknown), (unknown), D. Runge, Milka Marinova, Dieter Lütjohann, H K Kroemer, Werner Siegmund	33
9	Contribution of N-Glucuronidation to Efavirenz EliminationIn Vivoin the Basal and Rifampin-Induced Metabolism of Efavirenz 2011 ·Antimicrobial Agents and Chemotherapy ·Doo‐Yeoun Cho, Evan T. Ogburn, David Jones, Zeruesenay Desta	29
10	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole 2010 ·British Journal of Clinical Pharmacology ·Landry K. Kamdem, Yong Liu, Vered Stearns, Susan Kadlubar, Jacqueline Ramı́rez, Stacie C. Jeter, (unknown), Bryan A. Ward, Evan T. Ogburn, Mark J. Ratain, David A. Flockhart, Zeruesenay Desta	60
11	Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation 2010 ·Drug Metabolism and Disposition ·Evan T. Ogburn, David Jones, (unknown), Cong Xu, Yingying Guo, Zeruesenay Desta	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact